Search results for "PEPTIDE"

showing 10 items of 4589 documents

Ezetimibe/Simvastatin 10/20 mg versus Rosuvastatin 10 mg in high-risk hypercholesterolemic patients stratified by prior statin treatment potency

2010

Abstract Objective This post-hoc analysis compared the lipid-altering efficacy of Ezetimibe/Simvastatin 10/20 mg (EZ/Simva) versus Rosuvastatin 10 mg (Rosuva) in patients stratified by statin potency/dose prior to randomization. Methods Patients with elevated low-density lipoprotein cholesterol (LDL-C) despite prior statin treatment (n = 618) were randomized 1:1 to EZ/Simva 10/20 mg or Rosuva 10 mg for 6 weeks. Percent change from baseline in lipids and attainment of lipid targets were assessed within each subgroup (low potency n = 369, high potency n = 249). Consistency of the treatment effect across subgroups was evaluated by testing for treatment-by-subgroup interaction. No multiplicity …

AdultMaleSimvastatinmedicine.medical_specialtySettore MED/09 - Medicina InternaStatinRandomizationAdolescentmedicine.drug_classEndocrinology Diabetes and MetabolismHypercholesterolemiaClinical BiochemistryUrologyPharmacologyYoung AdultEndocrinologyEzetimibemedicineHumansPotencyRosuvastatinRosuvastatin Calciumlcsh:RC620-627AgedBiochemistry medicalAged 80 and overSulfonamidesSimvastatin; Ezetimibe;hypercholesterolemic;ChemistryhypercholesterolemicResearchAnticholesteremic AgentsBiochemistry (medical)nutritional and metabolic diseasesMiddle AgedEzetimibeFluorobenzeneslcsh:Nutritional diseases. Deficiency diseasesRosuvastatin CalciumPyrimidinesTreatment OutcomeSimvastatinAzetidinesFemalelipids (amino acids peptides and proteins)Ezetimibe/simvastatinHydroxymethylglutaryl-CoA Reductase Inhibitorsmedicine.drugLipids in Health and Disease
researchProduct

Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately c…

2009

SUMMARY Aims: To evaluate the efficacy of switching from a previous statin monotherapy to ezetimibe ⁄simvastatin (EZE ⁄SIMVA) 10 ⁄20 mg vs. rosuvastatin (ROSUVA) 10 mg. Methods: In this randomised, double-blind study, 618 patients with documented hypercholesterolaemia [low-density lipoprotein cholesterol (LDL-C) ‡ 2.59 and £ 4.92 mmol ⁄l] and with high cardiovascular risk who were taking a stable daily dose of one of several statin medications for ‡ 6 weeks prior to the study randomisation visit entered a 6-week open-label stabilisation ⁄screening period during which they continued to receive their prestudy statin dose. Following stratification by study site and statin dose ⁄potency, patien…

AdultMaleSimvastatinmedicine.medical_specialtyimvastatinStatinmedicine.drug_classHypercholesterolemiaCoronary Artery DiseaseGastroenterologyhypercholesterolaemicchemistry.chemical_compoundDouble-Blind MethodEzetimibeRisk FactorsInternal medicinemedicineHumansRosuvastatinRosuvastatin CalciumAgedAged 80 and overSulfonamidesbiologybusiness.industryCholesterolCholesterol LDLGeneral MedicineMiddle AgedFluorobenzenesRosuvastatin CalciumPyrimidinesTreatment OutcomeEndocrinologychemistrySimvastatinHMG-CoA reductasebiology.proteinAzetidinesDrug Therapy CombinationFemalelipids (amino acids peptides and proteins)Ezetimibe/simvastatinHydroxymethylglutaryl-CoA Reductase Inhibitorsbusinessezetimibemedicine.drugInternational Journal of Clinical Practice
researchProduct

Association between the TaqIB polymorphism in the cholesteryl ester transfer protein gene locus and plasma lipoprotein levels in familial hypercholes…

2001

Abstract Cholesteryl ester transfer protein (CETP) facilitates the exchange of triglycerides (TG) and cholesteryl ester between lipoprotein particles. Subjects with familial hypercholesterolemia (FH) have been reported to have higher CETP activities, which could contribute to the lower high-density lipoprotein-cholesterol (HDL-C) levels and increased cardiovascular risk observed in some of these patients. Several polymorphisms have been reported in the CETP locus; the common TaqlB polymorphism is associated, in normolipidemic subjects, with decreased CETP activity and levels and with increased HDL-C levels. No data is available on the influence of this polymorphism in FH subjects. We have e…

AdultMaleSite-Specific DNA-Methyltransferase (Adenine-Specific)medicine.medical_specialtyGenotypeApolipoprotein BLipoproteinsEndocrinology Diabetes and MetabolismPopulationFamilial hypercholesterolemiaHyperlipoproteinemia Type IIchemistry.chemical_compoundEndocrinologyInternal medicineCholesterylester transfer proteinmedicineHumanseducationNational Cholesterol Education ProgramAllelesGlycoproteinseducation.field_of_studyPolymorphism Geneticbiologymedicine.diagnostic_testmedicine.diseaseCholesterol Ester Transfer ProteinsCholesterolEndocrinologychemistryCardiovascular DiseasesSpainbiology.proteinCholesteryl esterFemalelipids (amino acids peptides and proteins)Carrier ProteinsLipid profileLipoproteinMetabolism
researchProduct

NF-κB protects Behçet's disease T cells against CD95-induced apoptosis up-regulating antiapoptotic proteins

2005

Objective To determine whether prolongation of the inflammatory reaction in patients with Behcet's disease (BD) is related to apoptosis resistance and is associated with the up-regulation of antiapoptotic factors. Methods The percentage of cell death was evaluated by flow cytometry in peripheral blood mononuclear cells from 35 patients with BD and 30 healthy volunteers. The expression levels of antiapoptotic factors and NF-κB regulatory proteins were measured using Western blotting and immunohistochemical analyses. To down-regulate NF-κB nuclear translocation, BD T lymphocytes were exposed in vitro to thalidomide and subjected to transfection with NF-κB small interfering RNA. Results Althou…

AdultMaleSmall interfering RNAProgrammed cell deathT-LymphocytesT cellImmunologyCASP8 and FADD-Like Apoptosis Regulating Proteinbcl-X ProteinApoptosisCaspase 3TransfectionCaspase 8RheumatologyHumansImmunology and AllergyMedicinePharmacology (medical)fas ReceptorRNA Small InterferingCells CulturedDose-Response Relationship Drugbusiness.industryBehcet SyndromeIntracellular Signaling Peptides and ProteinsNF-kappa BTransfectionFlow CytometryFas receptorThalidomideUp-Regulationmedicine.anatomical_structureGene Expression RegulationProto-Oncogene Proteins c-bcl-2ApoptosisImmunologyLeukocytes MononuclearCancer researchFemalebusinessArthritis & Rheumatism
researchProduct

Antiplatelet effects of intravenous iloprost in patients with peripheral arterial obliterative disease

1986

The dose-dependent inhibition of platelet aggregation by the chemically stable, prostacyclin-mimetic, iloprost, was studied in patients suffering from stage II-III peripheral arterial obliterative disease (PAOD). The study was designed as a randomized placebo-controlled cross-over trial. Iloprost was administered i.v. to six patients at doses of 0.5, 1.0, 2.0 or 3.0 ng/kg X min for 4 h, with an interval of 2-3 days between the infusions. During iloprost infusion, systolic and diastolic arterial blood pressure, heart rate and blood flow in the affected limb remained unchanged. In contrast, there was a considerable, dose-dependent inhibition of ADP- and thrombin-induced platelet aggregation a…

AdultMaleTime FactorsPlatelet AggregationDiastoleHemodynamicsArterial Occlusive DiseasesPlaceboRandom AllocationDrug DiscoveryHeart ratemedicineHumansPlateletIloprostGenetics (clinical)AgedDose-Response Relationship Drugbusiness.industryHemodynamicsCardiovascular AgentsGeneral MedicineMiddle AgedEpoprostenolBlood pressureAnesthesiaCardiovascular agentDrug EvaluationMolecular MedicineFemalelipids (amino acids peptides and proteins)businesscirculatory and respiratory physiologyIloprostmedicine.drugKlinische Wochenschrift
researchProduct

Psychophysics, flare, and neurosecretory function in human pain models: capsaicin versus electrically evoked pain.

2007

Intradermal capsaicin injection (CAP) and electrical current stimulation (ES) are analyzed in respect to patterns and test-retest reliability of pain as well as sensory and neurosecretory changes. In 10 healthy subjects, 2 CAP (50 g) and 2 ES (5 to 30 mA) were applied to the volar forearm. The time period between 2 identical stimulations was about 4 months. Pain ratings, areas of mechanical hyperalgesia, and allodynia were assessed. The intensity of sensory changes was quantified by using quantitative sensory testing. Neurogenic flare was assessed by using laser Doppler imaging. Calcito- nin gene-related peptide (CGRP) release was quantified by dermal microdialysis in combination with an en…

AdultMaleTime FactorsSensory Receptor CellsCalcitonin Gene-Related PeptideModels NeurologicalPainStimulationSensory systemCalcitonin gene-related peptidechemistry.chemical_compoundmedicineNoxious stimulusLaser-Doppler FlowmetryPsychophysicsHumansPain MeasurementSkinNerve Fibers UnmyelinatedNeuronal Plasticitybusiness.industryNociceptorsMiddle AgedNeurosecretory SystemsElectric StimulationPeripheralAnesthesiology and Pain MedicineAllodyniaNeurologychemistryCapsaicinHyperalgesiaRegional Blood FlowAnesthesiaHyperalgesiaFemaleNeurology (clinical)medicine.symptomCapsaicinInflammation MediatorsbusinessThe journal of pain
researchProduct

Immobilisation of linear and cyclic RGD-peptides on titanium surfaces and their impact on endothelial cell adhesion and proliferation

2011

Functional coatings on titanium vascular stents and endosseous dental implants could probably enhance endothelial cell (EC) adhesion and activity with a shortening of the wound healing time and an increase of peri-implant angiogenesis during early bone formation. Therefore, the role of the structure of linear and cyclic cell adhesive peptides Arg-Gly-Asp (l-RGD and c-RGD) on differently pre-treated titanium (Ti) surfaces (untreated, silanised vs. functionalised with l- and c-RGD peptides) on EC cell coverage and proliferation was evaluated. After 24 h and after 3 d, surface coverage of adherent cells was quantifi ed and an alamarBlue® proliferation assay was conducted. After 24 h, l-RGD mod…

AdultMaleTime Factorslcsh:Diseases of the musculoskeletal systemSurface PropertiesAngiogenesisCelllcsh:Surgerychemistry.chemical_elementCoated Materials BiocompatibleRGD modificationCell AdhesionmedicineHumanstitaniumcyclicCells CulturedCell ProliferationCell growthlcsh:RD1-811AdhesionMolecular biologyendothelial cellsEndothelial stem cellimmobilisationmedicine.anatomical_structurelinearchemistryMicroscopy Electron ScanningFemalelcsh:RC925-935Cyclic RGDWound healingOligopeptidesBiomedical engineeringTitaniumEuropean Cells and Materials
researchProduct

Endothelium-independent contractions of human cerebral arteries in response to vasopressin.

1990

We studied the effects of vasopressin in isolated segments from branches (500-700 micrograms in external diameter) of human middle cerebral arteries obtained during autopsy of 15 patients who had died 3-8 hours before. Paired segments, one normal and the other de-endothelized by gentle rubbing, were mounted for isometric recording of tension in organ baths. In 11 normal segments, vasopressin produced concentration-dependent contractions with an EC50 of 7.0 X 10(-10) M. Removal of the endothelium from 12 segments did not significantly affect vasopressin-induced contractions. Vasopressin produced further contractions in arterial segments with (n = 4) or without (n = 5) endothelium precontract…

AdultMaleVasopressinmedicine.medical_specialtyEndotheliummedicine.drug_classVasopressinsCerebral arteriesNeuropeptideIn Vitro TechniquesPotassium Chloridemedicine.arteryInternal medicinemedicineHumansAgedAdvanced and Specialized NursingDose-Response Relationship Drugbusiness.industryOsmolar ConcentrationCerebral ArteriesMiddle AgedReceptor antagonistAcetylcholineArginine Vasopressinmedicine.anatomical_structureEndocrinologyVasoconstrictionMiddle cerebral arteryFemaleNeurology (clinical)Endothelium Vascularmedicine.symptomCardiology and Cardiovascular MedicinebusinessAcetylcholineVasoconstrictionmedicine.drugStroke
researchProduct

Effects of vasopressin on human renal arteries

1996

The effects of vasopressin were studied in isolated rings from branches (2-3 mm in external diameter) of human renal arteries obtained from 18 patients undergoing nephrectomy for non-obstructive neoplasia. In arterial rings under resting tension, vasopressin produced concentration-dependent and endothelium-independent contractions with an EC 50 of 9.1 x 10 -10 mol L -1 . The vasopressin V 1 receptor antagonist d(CH 2 ) 5 Tyr(Me)AVP (10 -6 mol L -1 ) displaced the control curve to vasopressin 564-fold to the right in a parallel manner. In precontracted arterial rings and previously treated with the V 1 antagonist (10 -6 mol L -1 ) vasopressin caused endothelium-independent relaxation. The re…

AdultMaleVasopressinmedicine.medical_specialtyVasopressinsmedicine.drug_classMuscle RelaxationIndomethacinClinical BiochemistryNeuropeptideBiologyBiochemistryNorepinephrineRenal ArteryInternal medicinemedicineHumansVasoconstrictor AgentsAgedVasopressin receptorKidneyDose-Response Relationship DrugAnti-Inflammatory Agents Non-SteroidalAntagonistGeneral MedicineMiddle AgedReceptor antagonistmedicine.anatomical_structureEndocrinologyCirculatory systemFemaleEndothelium Vascularmedicine.symptomhormones hormone substitutes and hormone antagonistsVasoconstrictionMuscle ContractionEuropean Journal of Clinical Investigation
researchProduct

High Serum Cholesteryl Ester Transfer Rates and Small High-Density Lipoproteins Are Associated With Young Age in Patients With Acute Myocardial Infar…

2007

Objectives Our aim was to characterize cholesteryl ester transfer protein (CETP) activity in the early phase of acute myocardial infarction (MI). Background Cholesteryl ester transfer protein catalyzes the transfer of cholesteryl esters from high-density lipoprotein (HDL) donors to apolipoprotein B-containing lipoprotein acceptors. Methods The CETP concentration, lipid profiles, and the rate of cholesteryl ester transfer (CET) from a tracer dose of radiolabeled HDL toward endogenous lipoproteins were determined within 24 h after symptom onset. Results Among 347 patients with first MI, CETP concentration, triglycerides, and non–HDL-cholesterol increased across tertiles of the CET rate, where…

AdultMaleVery low-density lipoproteinmedicine.medical_specialtyApolipoprotein BHeart disease[SDV]Life Sciences [q-bio]Myocardial Infarction030204 cardiovascular system & hematology03 medical and health scienceschemistry.chemical_compoundSex Factors0302 clinical medicineInternal medicineCholesterylester transfer proteinmedicineHumansProspective StudiesMyocardial infarctionAged030304 developmental biologyAged 80 and over0303 health sciencesbiologyCholesterolbusiness.industryAge FactorsMiddle Agedmedicine.diseaseCholesterol Ester Transfer ProteinsEndocrinologychemistrybiology.proteinCholesteryl esterFemalelipids (amino acids peptides and proteins)Lipoproteins HDLCardiology and Cardiovascular Medicinebusiness[SDV.AEN]Life Sciences [q-bio]/Food and NutritionLipoprotein
researchProduct